A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Encenicline (Primary)
  • Indications Cognition disorders; Schizophrenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COGNITIV SZ
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 24 Mar 2016 Top-line results published in a Forum Pharmaceuticals media release.
    • 24 Mar 2016 Primary endpoint (Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182) has not been met, according to a Forum Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top